Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting Report

Preclinical results of novel GRPR-targeted antagonists with modified binding sequences

Thomas Guenther, Sebastian Fischer, Roswitha Beck and Hans Wester
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 1054;
Thomas Guenther
1Technical University of Munich Garching Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sebastian Fischer
1Technical University of Munich Garching Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roswitha Beck
1Technical University of Munich Garching Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans Wester
2Technische Universitaet Muenchen Garching Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1054

Objectives: In addition to previous approaches aiming to improve the metabolic stability and pharmacokinetics of GRPR antagonists by C- or N-terminal modifications, we investigated in this study the introduction of unnatural amino acids (homoserine [Hse], citrulline [Cit], β-(3-benzo­thienyl)alanine [Bta] and α-methyl tryptophan [α-Me-Trp]) at the metabolically unstable Gln7-Trp8 sequence within the typically used Gastrin-releasing peptide receptor (GRPR) antagonist RM2 (DOTA-Pip5-D-Phe6-Gln7-Trp8-Ala9-Val10-Gly11-His12-Sta13-Leu14-NH2). The results of the development and evaluation of the five novel candidates for diagnosis and therapy of GRPR-based malignancies are given. Methods: All RM2-based compounds were synthesized by standard Fmoc-based solid-phase peptide synthesis (SPPS). Labeling with 177Lu was carried out at 95 °C within 10 min (1.0 M sodium acetate buffer, pH = 5.5, 0.1 M sodium ascorbate). GRPR affinity (IC50) and internalization (37 °C, 60 min) were determined using PC-3 cells. In addition, the lipophilicities (expressed as n-octanol/PBS partition coefficient; logD7.4) were determined and metabolic stabilities in vitro in human as well as murine plasma (3 d, 37 °C) were examined. Biodistribution studies were carried out at 1 h and 24 h p.i. on PC-3 tumor-bearing CB17-SCID mice. Results: Similar to the production of parent compound, the new RM2 derivatives were easily accessible by SPPS, resulting in 6-11% HPLC purified labeling precursor. Each of 177Lu-labeled compounds revealed suitable hydrophilicity (logD7.4) (177Lu-RM2: - 2.51 ± 0.02, 177Lu-Hse7-RM2: - 2.25 ± 0.06, 177Lu-Cit7-RM2: - 3.22 ± 0.15, 177Lu-Bta8-RM2: - 1.81 ± 0.02, 177Lu-α-Me-Trp8-RM2 = AMTG: - 2.28 ± 0.06 and 177Lu-DOTAGA-α-Me-Trp8-RM2 = AMTG2: - 2.51 ± 0.11. The GRPR affinity (IC50 [nM]) of the new compounds was high to moderate (Lu-RM2: 3.45 ± 0.18, Lu-Hse7-RM2: 19.7 ± 1.6; Lu-Cit7-RM2: 11.6 ± 2.1; Lu-Bta8-RM2: 4.63 ± 0.23; Lu-AMTG: 3.04 ± 0.08; Lu-AMTG2: 4.74 ± 0.23). Furthermore, internalization studies at 1 h confirmed antagonistic behavior for all evaluated compounds (specific internalization of 177Lu-RM2: 2.92 ± 0.20%; 177Lu-Hse7-RM2: 1.40 ± 0.16%; 177Lu-Bta8-RM2: 2.26 ± 0.18% and 177Lu-AMTG: 3.03 ± 0.18%). Compared to 177Lu-RM2, improved tumor-to-background (T/B) ratios at 1 h p.i. in mice was found in all organs for 177Lu-Hse7-RM2 and 177Lu-Bta8-RM2, whereas 177Lu-AMTG and 177Lu-AMTG2 showed enhanced T/B ratios in most organs (especially in blood and muscle) at 24 h p.i. Interestingly, studies on the metabolic stability of 177Lu-RM2 and 177Lu-AMTG in vitro in human and murine plasma revealed similar stability of both derivatives after 3 d (67% and 59%, respectively) in murine plasma, whereas stability in human plasma was significantly higher for 177Lu-AMTG after 3 d of incubation at 37 °C (36% and 92%, for 177Lu-RM2 and 177Lu-AMTG, respectively). Conclusion: Based on its high affinity, excellent biodistribution and improved metabolic stability, the novel GRPR-targeted antagonist AMTG as well as AMTG2 could be promising candidates for diagnosis and therapy of GRPR-expressing malignancies. In addition, Hse7-RM2 and Bta8-RM2 could be appropriate ligands for diagnostic purposes.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 61, Issue supplement 1
May 1, 2020
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Preclinical results of novel GRPR-targeted antagonists with modified binding sequences
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Preclinical results of novel GRPR-targeted antagonists with modified binding sequences
Thomas Guenther, Sebastian Fischer, Roswitha Beck, Hans Wester
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 1054;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Preclinical results of novel GRPR-targeted antagonists with modified binding sequences
Thomas Guenther, Sebastian Fischer, Roswitha Beck, Hans Wester
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 1054;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Rest Dose Spillover Correction of Stress Blood Flow Measurements in Digital Rb-82 Myocardial Perfusion PET/CT Imaging
  • Radiolabeled hyaluronic acid (HA) fragments for lymphatic imaging
  • Simplifying and Confirming Ketosis: A Quality Improvement Initiative in Cardiac Sarcoid Assessment
Show more

Preclinical Probes for Oncology (Poster Session)

  • pH-Triggered Assembly ofNatural Melanin Nanoparticle for Enhanced PET imaging
  • Positron Emission Tomography Imaging of Vascular Endothelial Growth Factor Receptor Expression with a new 64Cu labeled peptide
  • Probing-to-perturbing: Imaging-guided localized desilylation induces gasdermin release and pyroptotic cell death activates antitumor immunity
Show more Preclinical Probes for Oncology (Poster Session)

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire